Product Class:

NEBNext Direct® Cancer HotSpot Panel
Item# Description List Price Web Price Qty
E7000L NEBNext Direct Cancer HotSpot Panel - 24 rxns $5,855.00
$5,269.50
ADD TO CART
E7000S NEBNext Direct Cancer HotSpot Panel - 8 rxns $1,999.00
$1,799.10
ADD TO CART
E7000X NEBNext Direct Cancer HotSpot Panel - 96 rxns $15,991.00
$14,391.90
ADD TO CART
*On-line ordering is for Canadian customers only. Web pricing is applicable only to orders placed online at www.neb.ca

Please note, product now includes reagents for enzyme-based fragmentation.

Product Introduction

Target with precision.

The NEBNext Direct® Cancer HotSpot Panel employs a unique hybridization-based enrichment workflow that hybridizes baits directly to genomic DNA, without the need for upfront library preparation.

  • Generate a higher percentage of your sequencing reads aligning to your targets
  • Eliminate the need to over-sequence, reducing cost per sample
  • Obtain uniform sequencing of all targets, regardless of GC content
  • Save time with a 1-day workflow that combines enrichment with library preparation
  • Generate high quality libraries with limited input amounts and degraded DNA samples, including FFPE and ctDNA
  • Distinguish molecular duplicates, reducing false positive variants and improving sensitivity

Product Information

Description







Target enrichment, coupled with next generation sequencing (NGS), enables high-throughput, deep sequencing of genomic regions of interest. NEBNext Direct is a novel, hybridization-based capture method offering significant advantages over traditional in-solution hybridization and multiplex PCR protocols.

In the NEBNext Direct target enrichment approach (Figure 1), enzymatically nicked or Covaris® sheared DNA is hybridized to biotinylated oligonucleotide baits that capture both strands of the target DNA and define the 3´ ends of the regions of interest. After hybridization, the bait-target hybrids are bound to streptavidin beads and any 3´ off-target sequence is removed enzymatically. This combination of hybridization with enzymatic removal of 3´ off-target sequence enables greater sequencing specificity relative to conventional hybridization-based enrichment methods. The trimmed targets are then converted into Illumina-compatible libraries that include a 12 bp unique molecular identifier (UMI) in the Illumina i5 index location and an 8 bp sample barcode in the Illumina i7 index location. The NEBNext Direct enrichment method can be performed within one to two days and is compatible with most automated liquid handling instruments.

The NEBNext Direct Cancer HotSpot Panel is designed to enrich for DNA fragments across 190 common cancer targets from 50 genes, encompassing approximately 40 kb of sequence and including over 18,000 COSMIC features. This kit contains the oligonucleotides, beads, enzymes and buffers required to convert the desired fragments into a sequence-ready library for next-generation sequencing on the Illumina platform and is designed for PE75 or PE150 Illumina sequencing.

Advantages
  • Generate a higher percentage of your sequencing reads aligning to your targets
  • Eliminate the need to over-sequence, reducing cost per sample
  • Obtain uniform sequencing of all targets, regardless of GC content
  • Save time with a 1-day workflow that combines enrichment with library preparation
  • Generate high quality libraries with limited input amounts and degraded DNA samples, including FFPE and ctDNA
  • Distinguish molecular duplicates, reducing false positive variants and improving sensitivity


Figure 1. NEBNext Direct employs a fast hybridization-based workflow that combines capture with library preparation.

fast hybridization workflow


Table 1. Targets include regions from the following cancer-related genes:

Targets include regions from the following cancer-related genes


Figure 2. The NEBNext Direct Cancer HotSpot Panel demonstrates the ability to accurately detect a range of nucleic acid variants.

Allele Frequency
This figure shows the expected versus observed variant allele frequencies (VAF) across the range of well-characterized variants present in a pool of 24 HapMap samples screened against the NEBNext Direct Cancer HotSpot Panel. 100 ng of input DNA was used, samples were sequenced on the Illumina® MiSeq® using 2 x 75 bp sequencing, and standard data analysis and variant calling algorithms were used. We were able to successfully detect 100% of the 168 truth variants present across a range of 2-100% VAF. The high degree of linearity across this broad dynamic range demonstrates the ability of the NEBNext Direct Cancer HotSpot Panel to accurately predict variant allele frequencies across a broad dynamic range.


Figure 3. The NEBNext Direct Cancer HotSpot Panel delivers a high percentage of sequence reads mapping to targets, even with challenging sample types.

The NEBNext Direct Cancer HotSpot Panel delivers a high percentage of sequence reads mapping to targets, even with challenging sample types.

  • Graph shows the percentage of aligned sequence reads that map to the targets
  • 100 ng of DNA was used for each library preparation
  • Reads were generated on an Illumina® MiSeq® with 2 x 75 bp reads, 8 bp sample ID, and 12 bp unique molecule ID
  • Alignments were performed with BWA-MEM and PCR duplicates were filtered using the unique molecule IDs

Figure 4. The NEBNext Direct Cancer HotSpot Panel displays high uniformity of coverage across targets.

 Cancer HotSpot Panel displays high uniformity of coverage across targets.

  • Graph shows the percentage of target bases sequenced to at least 50%, 33%, and 25% of the mean read depth
  • 100 ng of DNA was used for each library preparation
  • Reads were generated on an Illumina MiSeq with 2 x 75 bp reads, 8 bp sample ID, and 12 bp unique molecule ID
  • Alignments were performed with BWA-MEM and PCR duplicates were filtered using the unique molecule IDs


Figure 5. The NEBNext Direct Cancer HotSpot Panel offers minimized bias across sequence content.

 minimized bias across sequence content

  • Graph shows the normalized depth of coverage of targets of varying GC content
  • 100 ng of DNA was used for each library preparation
  • Reads were generated on an Illumina MiSeq with 2 x 75 bp reads, 8 bp sample ID, and 12 bp unique molecule ID
  • Alignments were performed with BWA-MEM and PCR duplicates were filtered using the unique molecule IDs

ILLUMINA® and MISEQ® are registered trademarks of Illumina®, Inc.

Each set of reagents is functionally validated together through construction and sequencing of a transcriptome library and sequenced on a

Lot Control

The lots provided are managed separately and qualified by additional functional validation. Individual reagents undergo standard enzyme activity and quality control assays, and also meet stringent criteria in the additional quality controls listed on each individual component page

Reagents Supplied

The following reagents are supplied with this product:

Store at (°C) Concentration
NEBNext Direct® Bead Prep Buffer 4
NEBNext Direct® dA-Tailing Buffer 4
NEBNext Direct® Adaptor Ligation Buffer 4
NEBNext Direct® Cleaving Buffer 4
NEBNext Direct® Hybridization Wash (HW) 4
NEBNext Direct® Bead Wash 1 25
NEBNext Direct® Bead Wash 2 4
NEBNext Direct® 3´ Adaptor -20
NEBNext Direct® 5´ UMI Adaptor -20
NEBNext Direct® dA-Tailing Enzyme -20
NEBNext Direct® Ligase -20
NEBNext Direct® 5´ Blunting Enzyme Mix -20
NEBNext Direct® Cleaving Enzyme Mix -20
NEBNext Direct® Q5 Master Mix -20
NEBNext Direct® Index Primer Mix D01 -20 10 µM
NEBNext Direct® Index Primer Mix D02 -20 10 µM
NEBNext Direct® Index Primer Mix D03 -20 10 µM
NEBNext Direct® Index Primer Mix D04 10 µM
NEBNext Direct® Index Primer Mix D05 10 µM
NEBNext Direct® Index Primer Mix D06 10 µM
NEBNext Direct® Index Primer Mix D07 10 µM
NEBNext Direct® Index Primer Mix D08 10 µM
NEBNext Direct® Index Primer Mix D09 10 µM
NEBNext Direct® Index Primer Mix D10 10 µM
NEBNext Direct® Index Primer Mix D11 10 µM
NEBNext Direct® Index Primer Mix D12 10 µM
NEBNext Direct® Index Primer Mix D13 10 µM
NEBNext Direct® Index Primer Mix D14 10 µM
NEBNext Direct® Index Primer Mix D15 10 µM
NEBNext Direct® Index Primer Mix D16 10 µM
NEBNext Direct® Index Primer Mix D17 10 µM
NEBNext Direct® Index Primer Mix D18 10 µM
NEBNext Direct® Index Primer Mix D19 10 µM
NEBNext Direct® Index Primer Mix D20 10 µM
NEBNext Direct® Index Primer Mix D21 10 µM
NEBNext Direct® Index Primer Mix D22 10 µM
NEBNext Direct® Index Primer Mix D23 10 µM
NEBNext Direct® Index Primer Mix D24 -20
NEBNext Direct® Index Primer Mix Plate (NEB #E7000X) -20
NEBNext Sample Purification Beads 4
NEBNext Direct® Streptavidin Beads 4
NEBNext Direct® Hybridization Additive -20
NEBNext Direct® 5´ Blunting Buffer 4
NEBNext Direct Hybridization Buffer 4
NEBNext Direct® 3´ Blunting Enzyme Mix -20
NEBNext Direct Cancer HotSpot Baits -20
Product Categories:
Targeted Enrichment Products
Applications:
DNA Library Preparation,
Sample Prep & Target Enrichment for NGS,
Illumina Library Preparation

Properties & Usage

Materials Required but not Supplied

  • Covaris® microTubes or plate
  • 1X TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA)
  • Molecular grade ethanol
  • Molecular grade water
  • 96-well PCR plates (or PCR strip tubes)
  • Eppendorf® DNA LoBind® 2 ml tubes (VWR, cat#: 80077-234)
  • Additional microcentrifuge or conical tubes to prepare master mixes
  • 96-well plate magnet or PCR tube magnet
  • Microcentrifuge tube magnet
  • Agilent® High Sensitivity DNA Kit (Agilent, cat#: 5067-4626)

Required Equipment:

  • Covaris Focused-Ultrasonicator
  • Thermocycler programmable to 100 μl
  • Agilent Bioanalyzer® or similar instrument

Protocols, Manuals & Usage

Protocols

  1. Guidelines for Setting Up PCR Reactions (E7000X only)
  2. Protocol for NEBNext Direct® Cancer HotSpot Panel (NEB #E7000)

Manuals

The Product Manual includes details for how to use the product, as well as details of its formulation and quality controls.

Usage & Guidelines

Faqs & Troubleshooting

FAQs

  1. Where can I find the detailed FAQs for the NEBNext Direct® Cancer HotSpot Panel (NEB #E7000)?
  2. Can NEBNext Direct be applied for genotyping applications?

Troubleshooting

Quality, Safety & Legal

Quality Assurance Statement

Quality Control tests are performed on each new lot of NEB product to meet the specifications designated for it. Specifications and individual lot data from the tests that are performed for this particular product can be found and downloaded on the Product Specification Sheet, Certificate of Analysis, data card or product manual. Further information regarding NEB product quality can be found here.

Specifications

The Specification sheet is a document that includes the storage temperature, shelf life and the specifications designated for the product. The following file naming structure is used to name these document files: [Product Number]_[Size]_[Version]

Certificate Of Analysis

The Certificate of Analysis (COA) is a signed document that includes the storage temperature, expiration date and quality controls for an individual lot. The following file naming structure is used to name these document files: [Product Number]_[Size]_[Version]_[Lot Number]

Safety DataSheets

The following is a list of Safety Data Sheet (SDS) that apply to this product to help you use it safely.

Legal and Disclaimers

This product is covered by one or more patents, trademarks and/or copyrights owned or controlled by New England Biolabs, Inc (NEB).

While NEB develops and validates its products for various applications, the use of this product may require the buyer to obtain additional third party intellectual property rights for certain applications.

For more information about commercial rights, please contact NEB's Global Business Development team at [email protected].

This product is intended for research purposes only. This product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Licenses


This product is covered by one or more patents.

This product is licensed from Bio-Rad Laboratories, Inc., under U.S. Pat. Nos. 6,627,424, 7,541,170, 7,670,808, 7,666,645 and corresponding patents in other countries for use only in: (a) standard (not real-time) PCR in the research field only, but not real time PCR or digital PCR; (b) real-time PCR for use as a library preparation quantitation tool in Next Generation Sequencing workflows; (c) any in-vitro diagnostics applications, except for applications using real-time PCR or digital PCR; and (d) any non-PCR applications in DNA sequencing, isothermal amplification, and the production of synthetic DNA.